{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '94', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'A description of the adaptations and iRECIST process is provided in Appendix 6, with', 'additional details in the iRECIST publication [Seymour, L., et al 2017]. A summary of scans', 'and treatment requirements after first radiologic evidence of progression is provided in', 'Table 5.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '95', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 5 Summary of Imaging and Treatment Requirements After First Radiologic Evidence of Progression', 'Clinically Stable', 'Clinically Unstable', 'Imaging', 'Treatment', 'Imaging', 'Treatment', 'First radiologic evidence of PD', 'Submit the imaging to BICR', 'May continue study intervention at', 'No additional imaging', 'Discontinue treatment', 'by RECIST 1.1 per investigator', 'for verification.', 'the discretion of the investigator', 'required.', 'assessment', 'Repeat imaging at 4 to', \"and after obtaining participant's\", '8 weeks to confirm PD per', 'consent.', 'iRECIST.', 'Repeat tumor imaging', 'No additional imaging', 'Discontinue treatment (exception is', 'No additional imaging', 'Not applicable', 'confirms PD (iCPD) by', 'required.', 'possible upon consultation with', 'required.', 'iRECIST per investigator', 'Sponsor).', 'assessment', 'Repeat tumor imaging shows', 'Repeat imaging at 4 to', 'Continue study intervention at the', 'No additional imaging', 'Discontinue treatment', 'iUPD by iRECIST per', '8 weeks to confirm PD.', \"investigator's discretion.\", 'required.', 'investigator assessment', 'Repeat tumor imaging shows', 'Continue regularly scheduled', 'Continue study intervention at the', 'No additional imaging', 'Discontinue treatment', 'iSD, iPR, or iCR by iRECIST', 'imaging assessments.', \"investigator's discretion.\", 'required.', 'per investigator assessment.', 'Abbreviations: iCPD = IRECIST-confirmed progressive disease; iCR = iRECIST complete response; iRECIST = adjusted Response Evaluation Criteria in Solid Tumors 1.1', 'for', 'immune-based therapeutics; iSD = iRECIST stable disease; iUPD = iRECIST unconfirmed progressive disease; PD = progressive disease; RECIST 1.1 = Response Evaluation', 'Criteria in Solid Tumors, version 1.1; VOP = verification of progression.', 'Note: If PD has been centrally verified, further management is performed by the site, based on iRECIST. Any further imaging should still be submitted to the central imaging', 'vendor, but no rapid review will occur. If RECIST 1.1 PD has not been centrally verified, ideally the site should continue treatment. Whether or not treatment continues, imaging', 'should be collected and submitted to the central imaging vendor with VOP request until RECIST 1.1 PD is verified by BICR.', 'As of amendment 007-06, imaging obtained on study will be submitted to the imaging vendor but these will not be assessed for verification of progression. This table was', 'updated accordingly.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '96', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.2.1.7', 'Tumor Tissue Collection for PD-L1 Status', 'Participation in this study will be dependent upon supplying tumor tissue for PD-L1 testing', 'from locations not radiated before biopsy; formalin-fixed specimens after the participant has', 'been diagnosed with metastatic disease will be preferred for determination of PD-L1 status', 'before randomization. Biopsies obtained before receipt of fadjuvant/neoadjuvant', 'chemotherapy will be permitted if recent biopsy is not feasible.', 'All participants should submit either a newly obtained core or excisional biopsy or archival', 'tissue (fine-needle aspiration is not adequate for both archival and new tissue samples) to a', 'central laboratory for characterization of PD-L1 status before treatment allocation.', 'A fine-needle aspirate, frozen sample, plastic-embedded sample, cell block, clot, bone, bone', 'marrow, cytologic specimen, decalcified or formalin-fixed sample that was frozen at any', 'point will not be acceptable for analysis.', 'Note: Submission of formalin-fixed paraffin-embedded tumor tissue sample blocks are', 'preferred; if submitting unstained slides, the slides should be freshly cut and submitted to the', 'testing laboratory within 14 days from the site slide section date; otherwise, a new specimen', 'will be requested.', 'If the sample is determined to be nonevaluable before testing by the central laboratory, a new', 'sample should be submitted if available.', 'The central vendor PD-L1 TPS results of participants will be blinded to the investigator. The', 'Sponsor acknowledges that because of the commercial availability of PD-L1 testing assays, it', \"is possible that the investigator may know a participant's TPS before screening. This risk is\", 'seen as acceptable, as the treatment interventions are hypothesized to provide benefit', 'regardless of TPS.', '8.2.2', 'Patient-reported Outcomes', 'NOTE: As of Amendment 007-06, PROs will no longer be collected. This section is no', 'longer applicable.', 'The EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D-5L questionnaires will be', 'administered by trained site personnel and completed electronically by participants in the', 'following order: EORTC QLQ-C30, EORTC QLQ-LC13, and lastly EQ-5D-5L. The', 'questionnaires should be administered before dosing at every cycle through Cycle 17, then', 'every other cycle through Cycle 35 (eg, Cycles 1-17, 19, 21, 23, 25, 27, 29, 31, 33, and 35),', 'at the Treatment Discontinuation Visit, and at the 30-day Safety Follow-up Visit.', 'If the Treatment Discontinuation Visit occurs 30 days from the last dose of study', 'intervention, at the time of the mandatory Safety Follow-up Visit, the electronic', 'patient-reported outcomes (ePROs) do not need to be repeated.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}